NCT00256113已完成3 期
An Eight-Week, Multicenter, Double-blind, Placebo-controlled Study Evaluating the Efficacy, Safety, and Tolerability of One Fixed 100 mg Dose of Saredutant in Patients With Major Depressive Disorder
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 467
- 试验地点
- 8
- 主要终点
- The primary outcome of the study is the change from baseline to Day 56 of treatment in the Hamilton Depression Rating Scale (HAM-D) total score.
研究概览
简要总结
The purpose of the study is to evaluate the efficacy and safety of saredutant (or SR48968C) in patients with depression.
The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in patients with depression.
The secondary objectives are to evaluate the safety of saredutant, to evaluate the efficacy of saredutant on disability and quality of life in patients with depression, and to evaluate blood levels of saredutant.
详细描述
The study is a multicenter, multicountry, randomized, parallel-group, double blind, placebo and paroxetine-controlled study consisting of three segments (A, B, and C). Segment A is a 1-week, placebo, single-blind period and Segment B is an 8-week, double blind period. Patients completing Segment B may be eligible for enrollment into Segment C, a 44-week, double blind extension. All randomized patients must complete a post-study visit 1 week after intake of the last dose of study medication.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1. Male or female patients.
- •2. 18 to 64 years of age.
- •3. Inpatients or outpatients.
- •4. Written informed consent from the patient and/or legally authorized representative.
- •5. Able to comply with the protocol and follow written and verbal instructions.
- •6. Subjects of childbearing potential must have a confirmed negative serum b-hCG test prior to entry into Segment B and must employ an acceptable method of birth control (e.g., oral, depot, or implanted contraceptive method, IUDs, sterilization, barrier methods in conjunction with spermicide).
- •7. Diagnosis of major depressive disorder, as defined by Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision criteria and confirmed by the semi-structured Mini International Neuropsychiatric Interview (MINI), recurrent episode for at least one month prior to the entry.
- •8. Minimum total score of 22 on the Montgomery-Asberg Depression Rating Scale (MADRS).
排除标准
- •1. Patients whose current depressive episode is diagnosed with psychotic features, catatonic features, seasonal pattern or post-partum onset.
- •2. The duration of the current depressive episode is greater than 2 years.
- •3. Patients who are currently suicidal or have a history of a suicide attempt within 3 years prior to entry.
- •4. Patients whose current depressive episode is secondary to a general medical disorder.
- •5. Patients with a history or presence of bipolar disorders or psychotic disorders according to the D and L criteria of the MINI.
- •6. Patients with alcohol dependence or abuse or substance dependence or abuse in the past 12 months except nicotine or caffeine dependence.
- •7. Patients with a history of failure to respond to treatment with paroxetine or other antidepressant medications.*
- •8. Patients who have used the following prior to entry into Segment B: any antipsychotic within 3 months,-fluoxetine within 35 days, -any monoamine oxidase inhibitor within 21 days, any other antidepressant, anxiolytic, sedative-hypnotic, or mood-stabilizer (lithium, anticonvulsants) within 7 days except permitted concomitant medications.
- •9. Females who are pregnant or breast-feeding.
- •10. Severe or unstable cardiovascular, renal, hepatic, respiratory, hematological, endocrinological, neurological, or other somatic disease that might interfere with the evaluation of study medication.
- •11. History of seizures other than a single childhood febrile seizure.
- •12. ECG abnormalities of potential clinical significance including a QT interval with Bazett's correction of 500 msec or more at entry.
- •13. Use of known inducers or potent inhibitors of CYP3A4 within 7 days of entry.
- •14. Use of drugs with known risk for Torsade de Pointes within 7 days of entry into Segment B.
- •15. Participation in a clinical trial of an experimental therapy within 30 days prior to entry or prior participation in a clinical trial of saredutant.
- •16. Patients with a positive HbsAg or anti-HCV antibody test at screening.
- •17. Patients with any of the following at screening: ALT >2 times the upper limit of the normal range (XULN), AST >2XULN, GGT >3XULN, total or conjugated bilirubin >ULN
结局指标
主要结局
The primary outcome of the study is the change from baseline to Day 56 of treatment in the Hamilton Depression Rating Scale (HAM-D) total score.
次要结局
- The main secondary outcomes are the changes from baseline to Day 56 of treatment in the HAM-D depressed mood item, the Montgomery Asberg Depression Rating Scale total, and the Clinical Global Impression Severity of Illness scores.
研究者
研究点 (8)
Loading locations...
相似试验
已完成
3 期
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With DepressionDepressive DisorderNCT00250601Sanofi460
已完成
3 期
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With DepressionDepressive DisorderNCT00250614Sanofi452
已完成
3 期
An Eight-Week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With DepressionDepressive DisorderNCT00250627Sanofi465
已完成
3 期
A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA)Depressive DisorderNCT00336713Sanofi430
已完成
3 期
A North-American Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety DisorderAnxietyNCT00390650Sanofi366